Literature DB >> 15773790

Current status of salvage cryoablation for prostate cancer following radiation failure.

Joseph L Chin1, Naji Touma.   

Abstract

The role of salvage cryoablation of the prostate for patients with clinically localized prostate cancer that have failed radiotherapy to the prostate is reviewed with reference to alternatives including salvage radical prostatectomy and brachytherapy. The diagnosis and work-up of local recurrence/persistence of cancer in the prostate are reviewed and the patient selection criteria for salvage cryoablation is discussed. Technical aspects of the cryoablation procedure along with the outcome in terms of cancer control and treatment-related complications are detailed. The five-year biochemical disease-free rate is approximately 40%. The complication rate is acceptable. Salvage cryoablation definitely has a role in the management of localized prostate cancer treatment failure following radiotherapy, especially in older patients and those with some comorbidities.

Entities:  

Mesh:

Year:  2005        PMID: 15773790     DOI: 10.1177/153303460500400210

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  3 in total

1.  Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis.

Authors:  John M Baust; Daniel P Klossner; Anthony Robilotto; Robert G Vanbuskirk; Andrew A Gage; Vladimir Mouraviev; Thomas J Polascik; John G Baust
Journal:  BJU Int       Date:  2011-08-26       Impact factor: 5.588

Review 2.  Locally ablative therapies for primary radiation failures: a review and critical assessment of the efficacy.

Authors:  William C Huang; Courtney L Lee; James A Eastham
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

3.  Integrin involvement in freeze resistance of androgen-insensitive prostate cancer.

Authors:  J G Baust; D P Klossner; R G Vanbuskirk; A A Gage; V Mouraviev; T J Polascik; J M Baust
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-01-12       Impact factor: 5.554

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.